All News

#ACR21 #Abstr0252 Let's examine our patients than relying on tests. In sJIA pts presenting with fever, clinical features (fever pattern, rash and MSK symptoms) distinguished inflammation vs infection but not CRP, ferritin and procalcitonin @RheumNow https://t.co/s61WGBVK73 https://t.co/qhN95GdwgJ

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
A key reason I'm looking forward to in-person conferences again, is so I don't have to perform the mental gymnastics and stress of ensuring I make all the sessions and meetings on time! 😂 ⏰UK colleagues- time difference for #ACR21 will be +5️hours from tomorrow! @RheumNow https://t.co/wl7ij3vyOU

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Top Influencers of #acr21: @ACRheum @rheum_cat @RheumNow @CreakyJoints @DoctorYasmin @KDAO2011 More 📊 https://t.co/vyMAwjKbqC

Links:

Symplur Hashtags healthhashtags ( View Tweet)

There is a strong association with pre-ICI autoantibody positivity and any-type irAE development as well as high specificity of RF and CCP for ICI-arthritis. Prospective evaluation of RF/CCP pre-treatment may be useful @RheumNow #ACR21 Abst#0440 https://t.co/P7L7pL1iuV

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

Excellent debate in #Lupus nephritis 6S214 with Wofsy, Isenberg & Costenbader. Q’s. What to do about Class V renal, many class III, IV LNdon’t go into sustained remission, cases of new onset LN in pts with #Belimumab ?more/less than expected, which drug to use @RheumNow #ACR21 https://t.co/tWbw79dE7d
Janet Pope Janetbirdope ( View Tweet)
Torgutalp et al. ⭐️Included Early axSpA - 166 nr-axSpA (symptom duration ≤5 y) and 135 with r-axSpA (symptom duration ≤10 y) from German Cohort ⭐️Assessed TNFI use over 2 years and has shown🔽 in radiographic sacroiliitis progression. Abst#0451 #ACR21 @RheumNow #ACRBest https://t.co/xP0wMLSyGw
swethaann23 swethaann23 ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers? ⬆️IL-22 in AxSpA vs. controls ⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP Abs#385 #ACR21 @RheumNow https://t.co/hNtStAluJH
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 #Abstr0189 Another case for early intervention. Median time-to-Rilonacept (IL1-i) monotherapy for recurrent pericarditis was 7.9 weeks! During this time, >94% pts discontinued steroid and/or colchicine either sequentially or concurrently @RheumNow https://t.co/ofi3Jtm6j6 https://t.co/b6PnFw4gUN

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Active RA w/ large joint swelling & co-existent CVD & diabetes associated with ⬆️risk of #AlzheimersDisease & related #dementia in RA pts. 👉~1300 patients 👉Among CVD conditions, #stroke & #CHF assoc w/ the risk of #dementia #ACR21 Abs#0284 @RheumNow https://t.co/N3x2ZtBFGe https://t.co/kFyf3A0gha

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment ⬆️ACR20 response compared to pbo ⬆️secondary endpoints ⭐️no new safety signals Abs#453 #ACR21 #ACRBest @RheumNow https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Abs 457 #ACR21 @rheumnow Exciting work by @alhkim and colleagues on SARS-CoV-2 Vaccination in CID patients - Most (90%) developed Ab response but with reduced titers - GC users including some low dose mounted low responses - TNFi reduced in vitro neutralization of delta variant https://t.co/fJxnKmbccc
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%reported a flare since the pandemic & 16% had COVID-19. 19% reported no changes to their care.76% reported a change in their mood& emotional health. Was your pts experience similar?

Olga Petryna DrPetryna ( View Tweet)

2 year study of AxSpA pts in clinical remission who tapered TNFi. ⭐️52% successfully tapered to either 2/3, 1/2 or 1/3 dose ⭐️Baseline physician global score independent predictor of successful tapering Abs#364 #ACR21 @RheumNow https://t.co/9Kti5JGMYr https://t.co/y1Uj2dTABC

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
In a newly diagnosed SLE patient with class IV nephritis, already on HCQ, in addition to GC's, would you... #ACR21 #GreatDebate @rheumnow #LupusNephritis

TheDaoIndex KDAO2011 ( View Tweet)

#ACR21 #ACRBest @Rheumnow Abst #0452 Raychaudhuri et al. TB-PET/CT indices ➡️ disease outcome measures in PsA Identifies synovitis, enthesitis, dactylitis, nail matrix inflammation of PsA as compared to RA and OA Future use as a diagnostic tool for early disease of PsA https://t.co/uLsAWEkboS
swethaann23 swethaann23 ( View Tweet)
@ericdeinmd @RheumNow *TICOSPA IMO, more an issue of poor tools for activity monitoring and insufficiently diverse toolbox. Works in RA as lots of choices and good activity measures. Until AxSpa has those, don’t see how we hope to meet “tight control”.

Ethan Craig rheumecraig ( View Tweet)

@RheumNow #acr21 abst 195 prospective study of JAKi for refractory Still’s in 7 pts suggests JAKs can be useful as an add on but not in monotherapy : partial response 57%& failure in43%. No patient achieved complete remission. steroids could be decreased by63%~ https://t.co/rYHVReRHvL
Olga Petryna DrPetryna ( View Tweet)
Irish registry of AS pts included 76 women who were pregnant ⭐️58% uncomplicated, 41.9% complicated, 11% multiple complications ⭐️frequency of miscarriage ⬆️ ⭐️complications included C-section, preterm, NICU admission #ACR21 @RheumNow Abs#369 https://t.co/90dolEeTIw
Robert B Chao, MD doctorRBC ( View Tweet)
#ClinicalPearl. During Q&A of abst#0457 Kim A, et al plenary at #ACR2021 #ACR21 Dr Kim said with 3rd #COVIDvaccination dose the pts who had little or no response to spike protein DID mount a response. 3rd dose in vulnerable pts works #ACRBest @RheumNow

Janet Pope Janetbirdope ( View Tweet)

×